Iconovo AB’s Post

A big step forward. Developing generic inhalation products is very challenging and requires in-depth and integrated expertise within device design, formulation and anslysis.

📢 On May 15, #ProximaResearch became a partner of the 29th Kazakhstan International Healthcare Exhibition #KIHE2024 💊🎤 Ekaterina Markova, Director of Proxima Research Kazakhstan, participated in a panel discussion on the topic “Analysis and development prospects of the pharmaceutical market”, where she presented analytics of the pharmaceutical market #MarketAudit of medicines for the 1st quarter of 2024 Read more about the event in the article: https://cutt.ly/MerpeyW3 ❗If you would like to see our presentation, please leave a “+” in the comments 📨

Biosimilars are biologic drugs that are highly similar to an already approved biologic drug and are transforming the pharmaceutical industry. As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems. These alternatives are typically less expensive than their reference products, significantly improving patient access to essential therapies, particularly for chronic conditions such as cancer and autoimmune diseases. Despite being similar, biosimilars must meet rigorous regulatory requirements to demonstrate safety, efficacy, and quality, although they do not require the same extensive clinical trials as the original drugs. The growth of the biosimilar market fosters competition, driving down prices further and ultimately benefiting consumers and healthcare providers while ensuring that patients receive effective treatments.

Biosimilars, which are biologic drugs that are highly similar to an already approved biologic drug, are transforming the pharmaceutical industry. As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems. This article delves into the impact of biosimilars on biologic drug development pipelines, exploring their benefits, challenges, and future prospects. https://lnkd.in/erxQeEyW

📢 𝗦𝘁𝗮𝘆 𝗜𝗻𝗳𝗼𝗿𝗺𝗲𝗱: 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗡𝗲𝘄𝘀 𝗥𝗼𝘂𝗻𝗱𝘂𝗽 📢 16th Oct 2024 - Discover the latest advancements in the pharmaceutical industry with our daily news update. Our roundup includes crucial FDA designations, innovative drug developments, and impactful clinical trial outcomes analysis. Stay ahead and grow faster. #pharmanews #biopharma #fdaapprovals #clinicaltrials #drugdevelopment #thelansis #pancreaticcancer #friedreichataxia #glioblastoma #retinitispigmentosa #essclc #transthyretinamyloidosis

Innovation and Pharmaceutical Development: Pioneering New Frontiers in Medicine In today's rapidly evolving pharmaceutical landscape, innovation stands as the cornerstone of progress and success. The realm of pharmaceutical development encompasses a multifaceted journey, from initial drug discovery to optimizing drug delivery mechanisms. This article delves into the pivotal role of innovation in shaping the future of medicine, drawing insights from esteemed thought leaders and well-established literature. https://lnkd.in/dmy_Pz_x

Biosimilars, which are biologic drugs that are highly similar to an already approved biologic drug, are transforming the pharmaceutical industry. As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems. This article delves into the impact of biosimilars on biologic drug development pipelines, exploring their benefits, challenges, and future prospects. https://lnkd.in/eN_6FvtH

Biosimilar medicines can help healthcare systems expand patient access to innovative biologics while generating vital cost savings. However, many critical biologics set to lose exclusivity currently do not have a biosimilar candidate in the pipeline. In an opinion piece with the European Pharmaceutical Review, our Global Head Biosimilars and Country President Austria, Peter Stenico, discusses the importance of addressing this 'biosimilar void'. Peter explains that by creating a favorable environment for biosimilars in Europe, we can attract more competition and help healthcare systems deliver on the rising demand for high-quality care while managing costs. To learn more, read Peter's article in full in EPR's latest Pharma Horizons report:  https://lnkd.in/eX-aqeJf #Sandoz #Biosimilars #PioneeringAccess 

I couldn't agree more with this thought-provoking article by my colleague Peter Stenico on the significance of biosimilar medicines in Europe. The 'biosimilar void' is a concerning issue that demands immediate attention. We cannot afford to overlook the potential damaging impact on our already-stretched healthcare systems. The importance of collaboration between regulators, government bodies, payors, and the industry is clear as ever. Together, we must create a sustainable European market that encourages more biosimilar competition. Let's leverage biosimilars to expand access, drive healthcare sustainability, and foster innovation.